Australia buys extra 20m Pfizer doses as it pivots from AstraZeneca

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Australia has finalised a deal to buy an extra 20 million doses of the Pfizer vaccine as it rapidly pivots away from its earlier plan to rely mainly on the AstraZeneca jab&period;<&sol;p>&NewLine;<p>Prime Minister Scott Morrison announced the deal just hours after saying Australia would stop using the AstraZeneca vaccine for people aged under 50&period;<&sol;p>&NewLine;<p>He said the deal means Australia will get a total of 40 million doses of the Pfizer vaccine by the end of the year&comma; enough to inoculate 20 million people in the nation of 26 million&period;<&sol;p>&NewLine;<p>Australia’s pivot came after the European Medicines Agency said this week it had found a &OpenCurlyDoubleQuote;possible link” between the AstraZeneca vaccine and rare blood clots&comma; though regulators in the United Kingdom and the European Union emphasised that the benefits of receiving the vaccine continue to outweigh the risks for most people&period;<&sol;p>&NewLine;<p>After the European agency’s declaration&comma; Australian drug regulators held a series of urgent meetings on Thursday and recommended the Pfizer vaccine become the preferred jab for people under 50&period;<&sol;p>&NewLine;<p>Mr Morrison said there was no prohibition on the AstraZeneca vaccine and the risk of side effects was remote&period; He said the change was being made out of an abundance of caution&period;<&sol;p>&NewLine;<p>The pivot represents a significant shift in Australia’s overall approach and is likely to delay plans to have every person in the country inoculated by October&period;<&sol;p>&NewLine;<p>A major part of Australia’s strategy had been the ability to make its own vaccines at home and not rely on shipments from abroad&period;<&sol;p>&NewLine;<p>It had planned to manufacture some 50 million doses of the AstraZeneca vaccine&comma; enough for 25 million people&period; Australia had made no plans to make any other vaccines at home&period;<&sol;p>&NewLine;<p>Even before the change&comma; the government was facing criticism for a rollout program that’s lagging behind those in most other developed nations&period; So far&comma; Australia has administered just over 1 million vaccine doses&period;<&sol;p>&NewLine;<p>Australia has managed to stamp out community spread of the virus&comma; allowing life to continue much as before the pandemic&period;<&sol;p>&NewLine;<p>AstraZeneca noted Australia’s decision to restrict the vaccine’s use was based on it having no community transmission&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;Overall&comma; regulatory agencies have reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks&comma;” the company said in a statement&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68ed0b74330db">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68ed0b74330db'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version